The influenza diagnostics
market is expected to reach USD 3.3 billion by 2024, according to a new report
by Grand View Research, Inc. Influenza, or "the flu," is an
infectious disease and affects the upper respiratory tract in humans. The disease
is common in children and elderly population (aged 65 years and above). The
disease has a huge impact on public health. Influenza A virus poses a greater
risk as compared to the influenza B virus. The B virus is responsible for 20%
to 25% of infections globally. The growth in the influenza diagnostic market is
attributed to factors such as emergence of technologically advanced diagnostic
tests with shorter turnaround time; initiatives by regulatory bodies, such as
CDC’s seasonal influenza vaccination for prevention and control of seasonal
influenza; and the demand created for influenza diagnosis in the flu season.
Rapid Influenza Diagnostic
Tests (RIDTs) accounted for the largest share in 2015. RIDTs are tests that
deliver accurate results in approximately 15 minutes. This factor deems them
efficient, which has resulted in the lucrative growth of this segment with the
fastest CAGR. Reverse transcription polymerase chain reaction (RT-PCR) holds
the second highest market share following RIDTs, and this can be attributed to
the fact that it provides detailed analytical results, sharper turnaround
times, and high throughput.
 |
| Global Influenza Diagnostics Market, 2014 - 2024 (USD Million) |
Hospitals held the highest
market share in 2015, but Point-of-Care Testing (POCT) is anticipated to
overtake and lead the market in the coming future, owing to the increasing
usage of POCT because of its ease of use and short turnaround times.
North America dominates the
market, due to a high focus of the government and healthcare bodies to control
influenza.
In depth research report on Influenza Diagnostics Market
Further Key Findings From the Study Suggest:
·
North America is anticipated to
dominate the global influenza diagnostics market. The high adoption rates of in
vitro diagnostics and presence of technologically advanced medical devices is
expected to drive growth in the region.
·
The Asia Pacific region is
anticipated to be the fastest growing region in the study period. This growth
is attributed to factors such as increasing initiatives by the countries to
counter the incidence of the disease. For instance, CDC reached a cooperative
agreement with South-East Asian Region to fund non research-related bilateral
influenza as a measure to respond to avian, seasonal, and pandemic influenza.
·
The RIDT segment is expected to
grow at a significant rate compared to others and accounts for the largest
share in 2015.
·
This market comprises several
local as well as global players. Some of the major players of this vertical
include Becton, Dickinson and Company, Roche Diagnostics, Alere, Quidel
Corporation, and Thermo Fisher Scientific.
Grand View Research has
segmented the influenza diagnostics market on the basis of test type, end use,
and region:
Test Type Outlook (Revenue, USD Million, 2013 - 2024)
·
RIDTs
·
RT-PCR
·
Cell Culture
·
Others
End-use Outlook (Revenue, USD Million, 2013 - 2024)
·
Hospital
·
Point-of-Care Testing
·
Laboratories
Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
o
Saudi Arabia
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
For more market analysis reports, please visit: http://www.grandviewresearch.com/
No comments:
Post a Comment